• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CAR T cells and targeted gene delivery: A theme for the Pharmaceuticals and Medical Devices Agency Science Board to address.

作者信息

Wakao Rika, Fukaya-Shiba Ai

机构信息

Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.

出版信息

Front Med (Lausanne). 2023 Apr 17;10:1141880. doi: 10.3389/fmed.2023.1141880. eCollection 2023.

DOI:10.3389/fmed.2023.1141880
PMID:37138754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10150382/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec22/10150382/bed3e29adccc/fmed-10-1141880-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec22/10150382/bed3e29adccc/fmed-10-1141880-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec22/10150382/bed3e29adccc/fmed-10-1141880-g0001.jpg

相似文献

1
CAR T cells and targeted gene delivery: A theme for the Pharmaceuticals and Medical Devices Agency Science Board to address.嵌合抗原受体T细胞与靶向基因递送：日本药品和医疗器械管理局科学委员会需探讨的一个主题。
Front Med (Lausanne). 2023 Apr 17;10:1141880. doi: 10.3389/fmed.2023.1141880. eCollection 2023.
2
Pharmaceuticals and Medical Devices Agency's horizon scanning and the Science Board: Cooperation toward extracellular vesicle-based products.药品和医疗器械局的前瞻性扫描与科学委员会：针对细胞外囊泡相关产品的合作。
Br J Clin Pharmacol. 2022 Mar;88(3):1392-1394. doi: 10.1111/bcp.15065. Epub 2021 Sep 15.
3
The Roles of Regulatory Science Research in Drug Development at the Pharmaceuticals and Medical Devices Agency of Japan.日本药品和医疗器械局监管科学研究在药物研发中的作用。
Ther Innov Regul Sci. 2013 Jan;47(1):19-22. doi: 10.1177/2168479012469950.
4
Future development of artificial organs related with cutting edge emerging technology and their regulatory assessment: PMDA's perspective.未来与前沿新兴技术相关的人工器官的发展及其监管评估：PMDA 的观点。
J Artif Organs. 2020 Sep;23(3):203-206. doi: 10.1007/s10047-020-01161-4. Epub 2020 Feb 28.
5
[Regulatory Science in Practice (Pharmaceuticals and Medical Devices Agency)].[实践中的监管科学（药品和医疗器械局）]
Yakugaku Zasshi. 2017;137(4):439-442. doi: 10.1248/yakushi.16-00244-4.
6
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.儿童和青少年癌症嵌合抗原受体T细胞药物开发儿科战略论坛：ACCELERATE与欧洲药品管理局合作，并由美国食品药品监督管理局参与。
Eur J Cancer. 2022 Jan;160:112-133. doi: 10.1016/j.ejca.2021.10.016. Epub 2021 Nov 25.
7
Use of the Internet in scanning the horizon for new and emerging health technologies: a survey of agencies involved in horizon scanning.利用互联网扫描新出现的卫生技术领域：对参与领域扫描的机构的一项调查
J Med Internet Res. 2003 Jan-Mar;5(1):e6. doi: 10.2196/jmir.5.1.e6.
8
Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan.对日本《药品、医疗器械及其他治疗产品法》的考量与期望。
Regen Ther. 2015 May 15;1:80-83. doi: 10.1016/j.reth.2015.04.001. eCollection 2015 Jun.
9
generated human CAR T cells eradicate tumor cells.生成的人嵌合抗原受体T细胞可根除肿瘤细胞。
Oncoimmunology. 2019 Oct 10;8(12):e1671761. doi: 10.1080/2162402X.2019.1671761. eCollection 2019.
10
A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?嵌合抗原受体 T 细胞疗法概论：对病理学家意味着什么？
Arch Pathol Lab Med. 2021 Jun 1;145(6):704-716. doi: 10.5858/arpa.2019-0632-CP.

引用本文的文献

1
Expanding Immunotherapy Beyond CAR T Cells: Engineering Diverse Immune Cells to Target Solid Tumors.将免疫疗法扩展至CAR-T细胞之外：改造多种免疫细胞以靶向实体瘤
Cancers (Basel). 2025 Sep 5;17(17):2917. doi: 10.3390/cancers17172917.
2
Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.溶瘤病毒和嵌合抗原受体T细胞基因治疗进展及治疗相关分组
Curr Issues Mol Biol. 2025 Apr 10;47(4):268. doi: 10.3390/cimb47040268.
3
State of the art in CAR-based therapy: In vivo CAR production as a revolution in cell-based cancer treatment.

本文引用的文献

1
Health horizons: Future trends and technologies from the European Medicines Agency's horizon scanning collaborations.健康视野：欧洲药品管理局前瞻扫描合作中的未来趋势与技术
Front Med (Lausanne). 2022 Dec 8;9:1064003. doi: 10.3389/fmed.2022.1064003. eCollection 2022.
2
The landscape of mRNA nanomedicine.信使核糖核酸纳米药物的前景。
Nat Med. 2022 Nov;28(11):2273-2287. doi: 10.1038/s41591-022-02061-1. Epub 2022 Nov 10.
3
Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms.精准医疗：体内 CAR 疗法作为受体靶向载体平台的范例。
基于嵌合抗原受体（CAR）疗法的最新进展：体内CAR生成作为细胞癌症治疗的一场革命。
Cell Oncol (Dordr). 2025 Apr 22. doi: 10.1007/s13402-025-01056-7.
4
Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors.嵌合抗原受体T细胞疗法的进展：抗原选择、修饰及实体瘤的当前试验
Front Immunol. 2025 Jan 6;15:1489827. doi: 10.3389/fimmu.2024.1489827. eCollection 2024.
5
Translational PK-PD model for in vivo CAR-T-cell therapy delivered using CAR mRNA-loaded polymeric nanoparticle vector.使用负载CAR mRNA的聚合物纳米颗粒载体进行体内CAR-T细胞治疗的转化性药代动力学-药效学模型
Clin Transl Sci. 2024 Dec;17(12):e70101. doi: 10.1111/cts.70101.
6
CAR T Cell Nanosymbionts: Revealing the Boundless Potential of a New Dyad.嵌合抗原受体T细胞纳米共生体：揭示一种新型二元组合的无限潜力。
Int J Mol Sci. 2024 Dec 7;25(23):13157. doi: 10.3390/ijms252313157.
7
Application of novel CAR technologies to improve treatment of autoimmune disease.新型 CAR 技术在改善自身免疫性疾病治疗中的应用。
Front Immunol. 2024 Oct 9;15:1465191. doi: 10.3389/fimmu.2024.1465191. eCollection 2024.
8
Exploring the potential of the convergence between extracellular vesicles and CAR technology as a novel immunotherapy approach.探索细胞外囊泡与嵌合抗原受体（CAR）技术融合作为一种新型免疫治疗方法的潜力。
J Extracell Biol. 2024 Sep 26;3(9):e70011. doi: 10.1002/jex2.70011. eCollection 2024 Sep.
9
Genetic alteration of SJ293TS cells and modification of serum-free media enhances lentiviral vector production.SJ293TS细胞的基因改造和无血清培养基的改良可提高慢病毒载体的产量。
Mol Ther Methods Clin Dev. 2024 May 21;32(2):101270. doi: 10.1016/j.omtm.2024.101270. eCollection 2024 Jun 13.
10
Charting new paradigms for CAR-T cell therapy beyond current Achilles heels.为 CAR-T 细胞疗法绘制超越当前弱点的新范式。
Front Immunol. 2024 May 1;15:1409021. doi: 10.3389/fimmu.2024.1409021. eCollection 2024.
Mol Ther. 2022 Jul 6;30(7):2401-2415. doi: 10.1016/j.ymthe.2022.05.018. Epub 2022 May 20.
4
Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells.用于快速体内制造和释放 CAR-T 细胞的生物指令性可植入支架。
Nat Biotechnol. 2022 Aug;40(8):1250-1258. doi: 10.1038/s41587-022-01245-x. Epub 2022 Mar 24.
5
Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy.诱导性嵌合抗原受体T细胞有望取得突破，克服当前嵌合抗原受体T细胞疗法的障碍。
Front Oncol. 2022 Feb 10;12:809754. doi: 10.3389/fonc.2022.809754. eCollection 2022.
6
CAR T cells produced in vivo to treat cardiac injury.体内生成的 CAR T 细胞治疗心脏损伤。
Science. 2022 Jan 7;375(6576):91-96. doi: 10.1126/science.abm0594. Epub 2022 Jan 6.
7
Pharmaceuticals and Medical Devices Agency's horizon scanning and the Science Board: Cooperation toward extracellular vesicle-based products.药品和医疗器械局的前瞻性扫描与科学委员会：针对细胞外囊泡相关产品的合作。
Br J Clin Pharmacol. 2022 Mar;88(3):1392-1394. doi: 10.1111/bcp.15065. Epub 2021 Sep 15.
8
Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells.双特异性结合物导向慢病毒载体使 CAR-T 细胞的体内工程成为可能。
J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-002737.
9
AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia.AAV 介导的体内 CAR 基因治疗靶向人 T 细胞白血病。
Blood Cancer J. 2021 Jun 23;11(6):119. doi: 10.1038/s41408-021-00508-1.
10
In Situ Programming of CAR T Cells.CAR T 细胞的原位编程。
Annu Rev Biomed Eng. 2021 Jul 13;23:385-405. doi: 10.1146/annurev-bioeng-070620-033348. Epub 2021 Apr 16.